IP Library › Granted Patent US 12,240,829
Granted Patent B2
US 12,240,829 · App. 17/440,437 · Granted Mar 4, 2025

Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto

Inventors: Thota Ganesh (Atlanta, GA); Raymond J. Dingledine (Atlanta, GA); Radhika Amaradahi (Atlanta, GA); Shabber Mohammed (Atlanta, GA)
Assignee: Emory University
C07D401/14A61P35/00C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,829
App. No.
17/440,437
Granted
Mar 4, 2025
Kind
B2
Abstract

The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

Claims (15)

1. A compound having Formula III,

or pharmaceutically acceptable salt or prodrug thereof, wherein:

a dotted line represents a double or single bond,

n is 1, 2, 3, or 4;

Q is CH, N, or NX 6 ;

W is N or C;

R 1 , R 2 , and R 3 are each, the same or different, hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 1 , R 2 , and R 3 are optionally substituted with one or more, the same or different, R 10 ;

X 1 , X 2 , X 3 , and X 4 are each, the same or different, hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein X 1 , X 2 , X 3 , and X 4 are optionally substituted with one or more, the same or different, X 10 ;

X 5 and X 6 are each, the same or different, hydrogen or alkyl, wherein X 5 and X 6 are optionally substituted with one or more, the same or different, X 10 ;

X 10 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein X 10 is optionally substituted with one or more, the same or different, X 11 ;

X 11 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl;

R 10 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 10 is optionally substituted with one or more, the same or different, R 11 ;

R 11 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R 11 is optionally substituted with one or more, the same or different, R 12 ; and

R 12 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl.

2. A compound 4-(4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)-N-(2-(2-methyl-1H-indol-3-yl)ethyl)benzamide or salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: DINGLEDINE, RAYMOND J.; GANESH, THOTA; MOHAMMED, SHABBER; AMARADHI, RADHIKA
To: EMORY UNIVERSITY
Reel/Frame 058442/0039 →
Continuity (2)
Provisional Application 62821163 · Mar 20, 2019
Related Publication 20220162186A1 · May 26, 2022
References Cited (71)
US 5342851A · Sanfilippo · 1994 [cited by applicant]
US 9518044B2 · Jiang · 2016 [cited by applicant]
US 10040783B2 · Jiang · 2018 [cited by applicant]
US 10052332B2 · Ganesh · 2018 [cited by applicant]
US 10568889B2 · Ganesh · 2020 [cited by applicant]
US 11077120B2 · Ganesh et al. · 2021 [cited by applicant]
US 20050277773A1 · Kataoka · 2005 [cited by applicant]
US 20090023741A1 · Buchmann · 2009 [cited by applicant]
US 20090163545A1 · Goldfarb · 2009 [cited by applicant]
US 20170081314A1 · Jiang · 2017 [cited by applicant]
US 20200085837A1 · Ganesh · 2020 [cited by applicant]
US 20220000883A1 · Ganesh · 2022 [cited by applicant]
US 20220162186A1 · Ganesh · 2022 [cited by applicant]
CN 01157668 · 2008 [cited by applicant]
EP 2002838 · 2008 [cited by applicant]
EP 2014287 · 2009 [cited by applicant]
EP 2476667 · 2012 [cited by applicant]
JP 2008115088 · 2008 [cited by applicant]
WO 1999031064 · 1999 [cited by applicant]
WO 2004035525 · 2004 [cited by applicant]
WO 2008152097 · 2008 [cited by applicant]
WO 2008152099 · 2008 [cited by applicant]
WO 2009022104 · 2009 [cited by applicant]
WO 2009147121 · 2009 [cited by applicant]
WO 2010012396 · 2010 [cited by applicant]
WO 2010012397 · 2010 [cited by applicant]
WO 2010100606 · 2010 [cited by applicant]
WO 2012080220 · 2012 [cited by applicant]
WO 2012177618 · 2012 [cited by applicant]
WO 2015167825A1 · 2015 [cited by applicant]
Amaradhi et al. Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models, J. Med. Chem, 2020, 63, 1032-1050. [cited by applicant]
Amaradhi et al. Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties. ACS Pharmacol Transl Sci, 2022, 5, 118-133. [cited by applicant]
Baryawno et al. Tumor-growth—promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets, Neuro-Oncology, 10, 661-674, 2008. [cited by applicant]
Battaglia et al. Indole amide derivatives: synthesis, structure—activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists, Eur J Med Chem. 1999, 34(2) 93-105. [cited by applicant]
Chemical Abstracts, CAS Registry No. 749890-20-8, C18H16N6O, Benzamide, N-[2-(1H-indol-3-yl) ethyl]-4-(1H-tetrazol-1-yl)-, downloaded Feb. 21, 2019. [cited by applicant]
Fu et al. EP2 Receptor Signaling Regulates Microglia Death, Mol Pharmacol, 88: 161-170, 2015. [cited by applicant]
Ganesh et al. Development of second generation EP2 antagonists with high selectivity, Eur J Med Chem. 2014, 23, 82: 521-535. [cited by applicant]
Ganesh et al. Lead Optimization Studies of Cinnamic Amide EP2 Antagonists, J. Med. Chem., 2014, 57 (10), 4173-4184. [cited by applicant]
Ganesh et al. Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties, Mol. Pharmaceutics, 2018, 15, 5809-5817. [cited by applicant]
Hou et al. Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling? Biomedicine & Pharmacotherapy 156 (2022) 113966. [cited by applicant]
Hou et al Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma, 2022, Cell Reports 39, 111000, pp. 1-18 and e1-e5. [cited by applicant]
Jiang et al. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection, Trends in Pharmacological Sciences, 2013, vol. 34, No. 7, 413-420. [cited by applicant]
Jiang et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012, 109(8):3149-54. [cited by applicant]
Jiang et al. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus, Neurobiology of Disease, 76 (2015) 126-136. [cited by applicant]
Legriel. et al. Functional outcome after convulsive status epilepticus, Crit Care Med, 2010, vol. 38, No. 12, 2295. [cited by applicant]
Liang et al. Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease, The Journal of Neuroscience, 2005, 25(44): 10180-10187. [cited by applicant]
Qiu et al. Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth, Br J Pharmacol. 2019, 176:1680-1699. [cited by applicant]
Rojas et al. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus, Neuropharmacology. 2015, 93: 15-27. [cited by applicant]
Rojas et al.Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats, Neuropharmacology 110 (2016) 419e430. [cited by applicant]
Shishido et al. Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorganic & Medicinal Chemistry Letters 2007;18(3):1072-8. [cited by applicant]
Silva et al. Advances in prodrug design, Mini Rev Med Chem, 2005, 5(10):893-914. [cited by applicant]
Yang et al., Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 108:295-304 (2009). [cited by applicant]
Pubchem, Substance Record for SID 373402298. Available Date: May 25, 2018. [retrieved on May 4, 2020) Retrieved from the Internet: <URL: https://pubchem.ncbi.nlm.nih.gov/substance/373402298>. entire document. [cited by applicant]
Pubchem, Substance Record for SID 253164928. Available Date: Oct. 22, 2015. (retrieved on Jun. 23, 2020]. Retrieved from the Internet: <URL:https://pubchem .ncbi.nim .nih .gov/substance/253164928>. entire document. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2020/023659, mailed Jul. 17, 2020, 12 Pages. [cited by applicant]
Amaradhi Radhika et al: “Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models”, Journal of Medicinal Chemistry, vol. 63, No. 3, Jan. 6, 2020, pp. 103… [cited by applicant]
Extended European Search Report issued in EP20774593.6, mailed Oct. 25, 2022. [cited by applicant]
Battaglia et al. Indole amide derivatives: synthesis, structure—activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists, Eur J Med Chem., vol. 34, Issue 2, Feb. 1999, … [cited by applicant]
Fu et al. EP2 Receptor Signaling Regulates Microglia Death, Mol Pharmacol 88:161-170, Jul. 2015. [cited by applicant]
Ganesh et al. Development of second generation EP2 antagonists with high selectivity, Eur J Med Chem. Jul. 23, 2014; 82: 521-535. [cited by applicant]
Ganesh et al. Lead Optimization Studies of Cinnamic Amide EP2 Antagonists, J. Med. Chem., 2014,57 (10), pp. 4173-4184. [cited by applicant]
Ganesh, et al.., Peripherally restricted, highly potent, selective, aqueous-soluble EP2 antagonist with anti-inflammatory properties. Molecular pharmaceutics, 15(12), 2018, 5809-5817. [cited by applicant]
Rojas et al. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus, Neuropharmacology. Jun. 2015 93: 15-27. [cited by applicant]
Silva, A., Mini-Reviews in Medicinal Chemistry, 2005, vol. 5, pp. 893-014. [cited by applicant]
Yang (2009) Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 108:295-304. [cited by applicant]
Shishido, Yuji, et al. “Synthesis of benzamide derivatives as TRPV1 antagonists.” Bioorganic & medicinal chemistry letters 18.3 (2008): 1072-1078. [cited by applicant]
Database Registry Chem Abstract Service Ohio; database accession No. 749890-20-08, C18H16N6, Benzamide, Abstract. [cited by applicant]
Supplementary European Search Report issued for Application 15785214, dated Sep. 28, 2017. [cited by applicant]
Extended Supplementary European Search Report issued for Application No. 15785214, dated Oct. 10, 2018. [cited by applicant]
International Search Report and Written Opinion issued for Application No. PCT/US2015/026364, dated Nov. 5, 2015. [cited by applicant]
CAPLUS 2008:1508627. [cited by applicant]